National Cancer Institute (NCI)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Cancer Institute (NCI) sits in the top decile of US sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count).
National Cancer Institute (NCI): 3,257 sponsored US clinical trials, 326 recruiting.
National Cancer Institute (NCI) sponsors 3,257 registered US clinical trials on ClinicalTrials.gov, 326 of them currently recruiting, and 2,051 completed. 193 of these trials are in Phase 3-4 (later-stage) and 2,628 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Malignant Solid Neoplasm, with 67 trials.
Top-decile sponsor footprint
National Cancer Institute (NCI) ranks in the top decile of sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
3,257 total, page 20 of 66
Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors
NCT02631733
Collection of Malignant Ascites, Pleural Fluid, and Blood From People With Solid Tumors
NCT03189108
Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer
NCT02898207
Cervix Image Sharing Protocol (CISP)
NCT03179306
Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery
NCT02893930
PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer
NCT02933255
Retrospective Study of Viral Reactivation Across All Bone Marrow Transplant Protocols Since 2010
NCT03111745
Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia
NCT02484430
Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004
NCT03050814
Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
NCT02828358
Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma
NCT02788201
T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas
NCT03049449
Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer
NCT02844816
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
NCT02921269
Discovery and Validation of Plasma DNA Methylation Biomarker for Detection of Stomach Cancer
NCT03076567
Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas
NCT03030417
Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma
NCT02631746
Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
NCT02948426
Prospective Evaluation and Molecular Profiling in People With Gastric Tumors
NCT03027427
Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer
NCT02567409
E7 TCR T Cells for Human Papillomavirus-Associated Cancers
NCT02858310
Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer
NCT03030404
Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)
NCT02689453
Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer
NCT02921256
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
NCT02780804
CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer
NCT03002623
Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma
NCT02942264
Hyperthyroid Follow-Up Study
NCT02989103
Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer
NCT02598557
Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma
NCT02775812
Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma
NCT02568553
Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma
NCT02101905
Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
NCT02759731
Sapanisertib in Treating Patients With Stage IV or Recurrent Lung Cancer
NCT02417701
Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
NCT02503709
Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists
NCT02911155
Simvastatin in Reducing Pancreatitis in Patients With Recurrent, Acute or Chronic Pancreatitis
NCT02743364
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
NCT02595905
Natural History of and Specimen Banking for People With Tumors of the Central Nervous System
NCT02851706
Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer
NCT02520778
Avelumab for People With Recurrent Respiratory Papillomatosis
NCT02859454
Linkage of Medicaid Enrollment Information to Surveillance, Epidemiology and End Results Data
NCT02875327
Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors
NCT02810418
Self-Affirmation: Construct Validity
NCT02317367
Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma
NCT02798536
Helicobacter Pylori Genome Project (HpGP)
NCT02788214
Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed
NCT02761057
Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma
NCT02839681
Differential Influences of Integral and Incidental Emotion on Cancer-related Judgments and Decision Making
NCT02829554
A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
NCT02821754
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1199 |
| Phase 2 | 1429 |
| Phase 3 | 193 |
Therapeutic Areas
What is open in the National Cancer Institute (NCI) pipeline
326 recruiting of 3,257 indexed (10% open); 2,051 completed (63%).
Phase mix: 193 late (III/IV) vs 2,628 early (I/II) (early-phase heavy).
Top condition: Advanced Malignant Solid Neoplasm (67 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.